Many clinical trials have demonstrated that prenatal corticosteroids reduce the risk of RDS. The greatest benefit is seen when the interval between the start of treatment and delivery is more than 48 hours and less than seven days (RCOG, 1999). Steroids accelerate maturation of foetal lungs by stimulating type II pneumocytes to produce the phospholipids necessary for surfactant production